- FILTERS Advanced
- Product Type
- Clonality
- Application
- Species / Reactivity
- Source / Host
- Conjugation
- CE / IVD
- Clone ID
- Biosite Product Line
- Supplier
- EXCLUDE FILTERS
- Clonality
- Application
- Species / Reactivity
- Conjugation
- Clone ID
- Biosite Product Line
- Supplier
| Name | Art no | Species Reactivity | Application | Conjugation | Clone | Size | Price |
|---|---|---|---|---|---|---|---|
|
154-37164
|
|
ELISA, FC, IHC, IP, WB
|
|
IDEC-114 (Galiximab)
|
200 µg
|
||
|
Ab00126-35.0
|
human, monkey
|
FC
|
Unconjugated
|
10F381 (rituximab)
|
200 µg
|
||
|
Ab00126-26.0
|
human, monkey
|
FC
|
Unconjugated
|
10F381 (rituximab)
|
200 µg
|
||
|
Ab00126-26.0-BT
|
human, monkey
|
FC
|
Unconjugated
|
10F381 (rituximab)
|
1 mg
|
||
|
Ab00126-35.0-BT
|
human, monkey
|
FC
|
Unconjugated
|
10F381 (rituximab)
|
1 mg
|
||
|
154-37157
|
|
FC
|
|
10F381 (Rituximab)
|
200 µg
|
||
|
Ab00728-36.0-BT
|
human, monkey
|
Block, IP, FC
|
Unconjugated
|
hL22 (Epratuzumab)
|
1 mg
|
||
|
Ab00728-37.0-BT
|
human, monkey
|
Block, IP, FC
|
Unconjugated
|
hL22 (Epratuzumab)
|
1 mg
|
||
|
Ab00728-35.0
|
human, monkey
|
Block, IP, FC
|
Unconjugated
|
hL22 (Epratuzumab)
|
200 µg
|
||
|
Ab00728-36.0
|
human, monkey
|
Block, IP, FC
|
Unconjugated
|
hL22 (Epratuzumab)
|
200 µg
|
||
|
Ab00728-26.0-BT
|
human, monkey
|
Block, IP, FC
|
Unconjugated
|
hL22 (Epratuzumab)
|
1 mg
|
||
|
Ab00728-26.0
|
human, monkey
|
Block, IP, FC
|
Unconjugated
|
hL22 (Epratuzumab)
|
200 µg
|
||
|
Ab00728-37.0
|
human, monkey
|
Block, IP, FC
|
Unconjugated
|
hL22 (Epratuzumab)
|
200 µg
|
||
|
Ab00728-35.0-BT
|
human, monkey
|
Block, IP, FC
|
Unconjugated
|
hL22 (Epratuzumab)
|
1 mg
|
||
|
154-37158
|
|
FC, IP
|
|
hL22 (Epratuzumab)
|
200 µg
|
||
|
154-37169
|
|
FC
|
|
Daclizumab
|
200 µg
|
||
|
154-37170
|
|
FC, IF, IHC, WB
|
|
Basiliximab
|
200 µg
|
||
|
Ab00170-26.0-BT
|
human
|
IF, IHC, WB
|
Unconjugated
|
YTH 12.5
|
1 mg
|
||
|
Ab00170-26.0
|
human
|
IF, IHC, WB
|
Unconjugated
|
YTH 12.5
|
200 µg
|
||
|
154-37159
|
|
FC, IF
|
|
hP67.6 (Gemtuzumab)
|
200 µg
|
||
|
Ab00217-35.0
|
human, monkey
|
WB, IP, IF, IHC, FC
|
Unconjugated
|
MT310
|
200 µg
|
||
|
Ab00217-26.0-BT
|
human, monkey
|
WB, IP, IF, IHC, FC
|
Unconjugated
|
MT310
|
1 mg
|
||
|
Ab00217-37.0-BT
|
human, monkey
|
WB, IP, IF, IHC, FC
|
Unconjugated
|
MT310
|
1 mg
|
||
|
Ab00217-26.0
|
human, monkey
|
WB, IP, IF, IHC, FC
|
Unconjugated
|
MT310
|
200 µg
|
||
|
Ab00217-36.0-BT
|
human, monkey
|
WB, IP, IF, IHC, FC
|
Unconjugated
|
MT310
|
1 mg
|
||
|
Ab00217-35.0-BT
|
human, monkey
|
WB, IP, IF, IHC, FC
|
Unconjugated
|
MT310
|
1 mg
|
||
|
Ab00217-36.0
|
human, monkey
|
WB, IP, IF, IHC, FC
|
Unconjugated
|
MT310
|
200 µg
|
||
|
Ab00217-37.0
|
human, monkey
|
WB, IP, IF, IHC, FC
|
Unconjugated
|
MT310
|
200 µg
|
||
|
154-37160
|
|
ELISA, FC, IHC
|
|
CE9.1 (Clenoliximab)
|
200 µg
|
||
|
154-37161
|
|
FC, IHC, WB
|
|
YNB46.1.8 (Campath-9H)
|
200 µg
|
||
|
Ab00129-26.0-BT
|
human
|
FC, IP, IHC, Activation
|
Unconjugated
|
G28.5
|
1 mg
|
||
|
Ab00129-26.0
|
human
|
FC, IP, IHC, Activation
|
Unconjugated
|
G28.5
|
200 µg
|
||
|
Ab00129-36.0
|
human
|
FC, IP, IHC, Activation
|
Unconjugated
|
G28.5
|
200 µg
|
||
|
Ab00129-35.0-BT
|
human
|
FC, IP, IHC, Activation
|
Unconjugated
|
G28.5
|
1 mg
|
||
|
Ab00129-36.0-BT
|
human
|
FC, IP, IHC, Activation
|
Unconjugated
|
G28.5
|
1 mg
|
||
|
Ab00129-35.0
|
human
|
FC, IP, IHC, Activation
|
Unconjugated
|
G28.5
|
200 µg
|
||
|
Ab00129-37.0
|
human
|
FC, IP, IHC, Activation
|
Unconjugated
|
G28.5
|
200 µg
|
||
|
Ab00129-37.0-BT
|
human
|
FC, IP, IHC, Activation
|
Unconjugated
|
G28.5
|
1 mg
|
||
|
154-37156
|
|
IF
|
|
IDEC-131 (Toralizumab)
|
200 µg
|
||
|
154-37162
|
|
FC, WB
|
|
hu5c8 (Ruplizumab)
|
200 µg
|
||
|
Ab00124-26.0
|
human, monkey
|
FA, ELISA, IHC, FC, WB
|
Unconjugated
|
Alemtuzumab (Campath-1H)
|
200 µg
|
||
|
Ab00124-35.0
|
human, monkey
|
FA, ELISA, IHC, FC, WB
|
Unconjugated
|
Alemtuzumab (Campath-1H)
|
200 µg
|
||
|
Ab00124-35.0-BT
|
human, monkey
|
FA, ELISA, IHC, FC, WB
|
Unconjugated
|
Alemtuzumab (Campath-1H)
|
1 mg
|
||
|
Ab00124-26.0-BT
|
human, monkey
|
FA, ELISA, IHC, FC, WB
|
Unconjugated
|
Alemtuzumab (Campath-1H)
|
1 mg
|
||
|
Ab01039-26.0-BT
|
human, monkey
|
FC
|
Unconjugated
|
YTC 182.20
|
1 mg
|
||
|
Ab01039-35.0-BT
|
human, monkey
|
FC
|
Unconjugated
|
YTC 182.20
|
1 mg
|
||
|
BT-4UI1HO-50
|
virus
|
ELISA
|
Unconjugated
|
|
50ul
|
||
|
BT-4UI1HO-100
|
virus
|
ELISA
|
Unconjugated
|
|
100ul
|
||
|
154-37167
|
|
FC, IHC
|
|
h-R3 (Nimotuzumab)
|
200 µg
|
||
|
154-37165
|
|
ELISA, FC, WB
|
|
2F8 (Zalutumumab; HuMax-EGFR)
|
200 µg
|